Loading
This study tests TROP-2-directed treatment; the registry reports that it is recruiting.
The registry lists NCT07101432 as recruiting, last updated 2026-10-05. Enrolment is 33 planned participants, an estimate. Interventions: Fludarabine, Cyclophosphamide. Primary measures include Safety and Adverse Events (AEs). No results are posted in the registry; this does not exclude separate publications. The brief summary specifies TROP2 CAR/IL-15 TGFBR2-knockout cord-blood NK cells with radiation; the intervention list names only the lymphodepleting drugs.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-08. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/